News

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

Inc.’s Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins, like customer expansion, key product launches, increased market share, and industry-defining accomplishments. Companies from a wide range of industries – such as technology, healthcare, finance, and retail – have been recognized for their success and positive influence on the business world. The full list can be found on Inc.com and in the upcoming winter print edition of Inc. magazine.

ivWatch has over 20 years of research and development under its belt since its founding, in its single-minded pursuit of improving IV safety globally, securing 69 patents for its technology in the process. Among the milestones the company has reached:

  • Over 300,000 patients monitored to date.
  • 9 million hours of patient monitoring to date.
  • Comparing January – September 2023 vs. 2024, single-use sensors sold increased 83%.
  • The company has expanded its footprint beyond the U.S. and the technology is now available in the U.K., Ireland, the Netherlands, Belgium, United Arab Emirates, Saudi Arabia, Australia, New Zealand, Canada, Qatar, Israel, and Kuwait.
  • >430% growth in product evaluations comparing 2023 completed evaluations to the evaluations completed in 2024, as of July. The evaluations completed in 2023 were located in only two countries (US and UK); as of January – July 2024, completed evaluations took place in 13 countries. An estimated total for evaluations to be completed by the end of 2024 would exceed the previous year 10 times.
  • Reached Top Ten in 2024 Startup World Cup Grand Finale.

“Being named to Inc.’s Best in Business list is a tremendous honor, and I want to thank everyone at ivWatch for their unwavering dedication toward growing our company and inventing an entirely new category with a solution we believe in that everyone around the world will one day need and benefit from,”  said ivWatch CEO Gary Warren. “We’re on a mission to solve one of the biggest problems in healthcare by reducing IV injuries, and this recognition belongs to the passionate ivWatch team who have started a movement along with our customers to keep patients safe from IV harm.”

Inc.’s Best in Business Awards are open to companies of all sizes and types, in all industries and locations. Public, private, nonprofit, subsidiary, U.S.-based, and international companies are all encouraged to apply. Inc. editors and reporters hand-review every application and select Best in Business honorees that, in each of the award categories, have had an outstanding influence on their communities, their industries, the environment, or society as a whole.

“For over 40 years, Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman.

For more information or to see the complete list, please visit inc.com/best-in-business.

 

Read more here.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules